CS([C:5]1[N:10]=[C:9]([O:11][CH2:12][C:13]2[CH:18]=[CH:17][C:16]([F:19])=[C:15]([F:20])[CH:14]=2)[C:8]([C:21]2[CH:26]=[CH:25][C:24]([Cl:27])=[CH:23][CH:22]=2)=[C:7]([C:28]2[CH:33]=[CH:32][C:31]([Cl:34])=[CH:30][C:29]=2[Cl:35])[N:6]=1)(=O)=O.[CH2:36]([NH:38][CH2:39][CH3:40])[CH3:37]>C1COCC1>[CH2:36]([N:38]([C:5]1[N:10]=[C:9]([O:11][CH2:12][C:13]2[CH:18]=[CH:17][C:16]([F:19])=[C:15]([F:20])[CH:14]=2)[C:8]([C:21]2[CH:26]=[CH:25][C:24]([Cl:27])=[CH:23][CH:22]=2)=[C:7]([C:28]2[CH:33]=[CH:32][C:31]([Cl:34])=[CH:30][C:29]=2[Cl:35])[N:6]=1)[CH2:39][CH3:40])[CH3:37]2-(Methylsulfonyl)-4-(3,4-difluorobenzyloxy)-5-[4-chlorophenyl]-6-[2,4-dichlorophenyl]pyrimidine (Reference Example 6, 55 mg, 0.10 mmol) was treated with excess diethylamine in THF according to the same general procedure described in Example 31, Step A. Workup (solvent removal under reduced pressure) and flash column chromatography on silica gel (eluted with 87/13 hexanes/ethyl acetate) afforded the title compound. HPLC/MS: m/e=550 (M++1); Rt=4.48 min. 1H-NMR 500 MHz (CDCl3): δ 1.23 (t, J=7 Hz, 3H), 3.65 (q, J=7 Hz, 2H), 5.39 (s, 2H), 7.04 (d, J=8 Hz, 2H), 7.08 (d, J=8 Hz, 2H), 7.13-7.22 (m, 5H), 7.34 (d, J=2 Hz, 1H).
Loading…